stock & financial message boards
  Joined Today: 14

  Login  |  Registration |  Site Map  |  Stock Market Blogs reaching thousands of users every day  |  Recent Activity  |    |

Next » | All Messages |  ABCO Message Board Home | recommend post |  Ignore Poster

Message #1
From: NewsBot
Date: April 26, 2005 09:59:24 AM

ABCO The Advisory Board Company Reports Third Quarter Results for Fiscal 2005

The Advisory Board Company Reports Third Quarter Results for Fiscal 2005 Company Reports Quarterly Revenue Growth of 16% and Contract Value of $141 Million; Announces Guidance for 2005 Calendar Year and New Research Program WASHINGTON - PRNewswire-FirstCall - Feb. 7 WASHINGTON, Feb. 7 /PRNewswire-FirstCall/ -- The Advisory Board Company (NASDAQ:ABCO) today announced financial results for the third quarter of its fiscal year ending March 31, 2005. For the quarter ending December 31, 2004, revenues increased 16% to $36.2 million, from $31.3 million for the third quarter of fiscal 2004. Net income was $5.5 million, or $0.29 per diluted share, compared to $4.6 million, or $0.25 per diluted share in the same period a year ago. Pro forma net income for the quarter, which excludes stock option related expenses and includes income taxes at 41.0%, increased 27% to $5.9 million, or $0.32 per diluted share, from $4.7 million, or $0.25 per diluted share last year. Revenues for the nine months ended December 31, 2004, increased 16% to $103.9 million from $89.7 million in the nine months ended December 31, 2003. Net income for the period was $16.9 million, or $0.89 per diluted share, compared to $13.7 million, or $0.74 per diluted share, for the same period a year ago. Pro forma net income for the nine months was $17.3 million, or $0.91 per diluted share, versus $14.0 million, or $0.75 per diluted share, in the prior year. Contract value grew 17% to $141.0 million as of December 31, 2004, up from $120.5 million as of December 31, 2003. Frank Williams, Chairman and Chief Executive Officer of The Advisory Board Company, commented, "We are very pleased with our financial results for the December quarter as we achieved revenue growth of 16% and contract value growth of 17%. Our revenue growth was accompanied by strong margin expansion with pro forma operating margins of 25.1% and pro forma diluted EPS of $0.32, or 28% growth over the prior year period. Our performance was driven by cutting-edge research agendas and continued program innovation which led to strong renewal performance and continued growth across our program portfolio. Most importantly, we continue to see strong attachment to our model of providing proven best practices to address an increasingly complex array of strategic and operational issues across the healthcare landscape." He added, "I am also pleased to announce the launch of our newest research program, the Healthcare Philanthropy Program. This program is designed to aid member organizations in maximizing fundraising performance. Through best practice research, performance benchmarking data, and online tools, the program helps to bring greater business discipline and return on investment focus to healthcare philanthropy executives. We have already established a strong charter membership for the program, including Partners HealthCare in Boston, Sharp HealthCare in San Diego, Baylor Health Care, North Shore-Long Island Jewish Health System and Sutter Health in Sacramento. The program is off to a strong start, and we are very excited about its potential." The Company's effective tax rate increased during the three months ended December 31, 2004, as a result of legislation enacted during the quarter by the District of Columbia that disallows certain expected state tax deductions. The impact of the new legislation, together with adjustments made to certain deferred tax assets, caused the effective tax rate to increase to 43.9% for the quarter. Outlook for Calendar Year 2005 Although the Company operates on a fiscal year ending March 31, 2005, the Company is providing guidance for the calendar year 2005. The following table summarizes the Company's guidance for the twelve months ending December 31, 2005. Pro forma earnings per diluted share for each period presented exclude stock option related expenses and do not consider any share based compensation expense that may occur in 2005. Revenue and Pro Forma Earnings Per Diluted Share Targets Twelve Months Three Months Ending Ending March 31, June 30, September 30, December 31, December 31, 2005 2005 2005 2005 2005 Revenue (000's) $37,400 $38,000 $39,800 $41,300 $156,500 Pro forma earnings per diluted share $0.35 $0.33 $0.34 $0.37 $1.39 In addition, the Company expects pro forma income from operations of approximately $41 million for calendar year 2005 and an effective income tax rate of approximately 41% in the March quarter and 40.5% for the remaining nine months of calendar year 2005. These effective tax rates do not take into account rates that will be applicable dependent upon the District of Columbia's recognition of the Company's status as a Qualified High Technology Company (for further information please see Note 8 to the Company's quarterly report on Form 10-Q filed November 9, 2004). Mr. Williams concluded, "We are very excited about our research agenda in the coming year. Healthcare executives face a myriad of challenges from caring for a growing uninsured population and increasing malpractice costs to evaluating innovative clinical technology investments and deployment of information technology to improve efficiency and quality of care. Our ability to provide comprehensive decision support at a low cost as well as our expanding network of executive relationships provides a strong platform for 2005. As a result of our strong value proposition and unique business model, we remain confident in our ability to build a scalable growth company with outstanding products and services." Share Repurchase During the three months ended December 31, 2004, the Company repurchased 233,200 shares of its common stock at a total cost of approximately $8.0 million. For the twelve months ended December 31, 2004, the Company repurchased 1,402,808 shares of its common stock at a total cost of approximately $46.8 million. The Company will hold an investor conference call to discuss its third quarter performance this evening, February 7, 2005, at 5:30 p.m. Eastern Standard Time. The conference call will be available via live web cast on the Company's web site at http://www.advisoryboardcompany.com/ in the section entitled "Other Information" found under the tab "About Us." To participate by telephone, the dial-in number is 800-884-5695 and the access code is 14602347. Investors are advised to dial-in at least five minutes prior to the call to register. The web cast will be archived for seven days: from 7:30 p.m. Monday, February 7, until 7:30 p.m. Monday, February 14, 2005. About The Advisory Board Company The Advisory Board Company provides best practices research and analysis to the health care industry, focusing on business strategy, operations and general management issues. The Company provides best practices and research through discrete annual programs to a membership of more than 2,300 hospitals, health systems, pharmaceutical and biotech companies, health care insurers, and medical device companies in the United States. Each program typically charges a fixed annual fee and provides members with best practices, research reports, executive education and other supporting research services. The Company believes its calculations of pro forma income from operations, net income and diluted earnings per share provide additional information about the Company's ongoing operating performance as well as additional information to compare to prior periods. Pro forma results exclude stock option related expenses and charges recorded within the provision for income taxes discussed above. The pro forma disclosures include income taxes at an effective rate of 41% for fiscal year 2005. For historical results, a reconciliation between pro forma and GAAP is shown in the attached schedule. The Company is not able to reconcile its outlook for the remainder of calendar year 2005 to GAAP as stock option related expense is dependent upon a number of unknown factors, including the extent (if any) to which employee stock options are exercised and future stock price. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are hereby cautioned that these statements may be affected by certain factors, among others, set forth below and in the Company's filings with the Securities and Exchange Commission, and consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those indicated by forward-looking statements include, among others, the dependence on renewal of membership-based services, dependence on key personnel, the need to attract and retain qualified personnel, management of growth, new product development, competition, risks associated with anticipating market trends, industry consolidation, variability of quarterly operating results and various factors that could affect the estimated tax rate, including whether the District of Columbia recognizes the Company's status as a Qualified High-Tech Company. These factors are discussed more fully in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. THE ADVISORY BOARD COMPANY UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Three Months Nine Months Ending Selected Ending Selected December 31 Growth December 31 Growth 2004 2003 Rates 2004 2003 Rates Statements of Operations Revenues $36,206 $31,262 15.8% $103,911 $89,662 15.9% Cost of services 15,059 13,167 42,899 37,075 Member relations and marketing 7,454 6,538 20,743 18,152 General and administrative 4,214 4,185 12,357 11,841 Depreciation and loss on disposal of assets 400 292 1,392 1,112 Stock option related expense 316 122 316 443 Income from operations 8,763 6,958 26,204 21,039 Interest income 1,001 781 2,810 2,042 Income before provision for income taxes 9,764 7,739 29,014 23,081 Provision for income taxes (4,282) (3,134) (12,079) (9,346) Net income $5,482 $4,605 $16,935 $13,735 Earnings per share Basic $0.31 $0.29 $0.96 $0.89 Diluted $0.29 $0.25 16.0% $0.89 $0.74 21.6% Weighted average common shares outstanding Basic 17,452 15,641 17,553 15,426 Diluted 18,861 18,627 19,074 18,554 Percentages of Revenues Cost of services 41.6% 42.1% 41.3% 41.3% Member relations and marketing 20.6% 20.9% 20.0% 20.2% General and administrative 11.6% 13.4% 11.9% 13.2% Depreciation and loss on disposal of assets 1.1% 0.9% 1.3% 1.2% Income from operations 24.2% 22.3% 25.2% 23.5% Net income 15.1% 14.7% 16.3% 15.3% Contract Value (at end of period) $141,026 $120,504 17.0% RECONCILIATION OF PRO FORMA RESULTS (In thousands, except per share data) Pro forma data (1) (2): Income from operations $8,763 $6,958 $26,204 $21,039 Stock option related expense 316 122 316 443 Pro forma income from operations 9,079 7,080 26,520 21,482 Interest income 1,001 781 2,810 2,042 Pro forma income before provision for income taxes 10,080 7,861 29,330 23,524 Pro forma provision for income taxes (4,133) (3,184) (12,025) (9,527) Pro forma net income $5,947 $4,677 $17,305 $13,997 Pro forma earnings per share Basic $0.34 $0.30 $0.99 $0.91 Diluted $0.32 $0.25 28.0% $0.91 $0.75 21.3% Percentages of Revenues Pro forma income from operations (1) 25.1% 22.6% 25.5% 24.0% Pro forma net income (1)(2) 16.4% 15.0% 16.7% 15.6% (1) Excludes stock option related expense. (2) Includes taxes of 41.0% for the fiscal year ending March 31, 2005. THE ADVISORY BOARD COMPANY CONSOLIDATED BALANCE SHEETS (In thousands) December 31, March 31, 2004 2004 (unaudited) ASSETS Current assets: Cash and cash equivalents $37,801 $41,389 Marketable securities 3,023 3,737 Membership fees receivable, net 31,209 14,338 Prepaid expenses and other current assets 3,781 3,121 Deferred income taxes 19,231 17,123 Deferred incentive compensation 3,187 2,375 Total current assets 98,232 82,083 Fixed assets, net 9,273 6,701 Deferred income taxes, net of current portion 15,973 20,532 Marketable securities 94,720 94,683 Total assets $218,198 $203,999 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Deferred revenues $87,176 $72,410 Accounts payable and accrued liabilities 8,110 8,262 Accrued incentive compensation 8,017 7,704 Total current liabilities 103,303 88,376 Long-term liabilities: Other liabilities 1,137 - Total liabilities 104,440 88,376 Stockholders' equity: Common stock 182 183 Additional paid-in capital 105,767 88,885 Retained earnings 21,513 37,694 Accumulated elements of comprehensive income 11 1,031 Treasury stock (13,715) (12,170) Total stockholders' equity 113,758 115,623 Total liabilities and stockholders' equity $218,198 $203,999 THE ADVISORY BOARD COMPANY UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Nine Months Ended December 31, 2004 2003 Cash flows from operating activities: Net income $16,935 $13,735 Adjustments to reconcile net income to net cash provided by operating activities - Depreciation 1,276 1,112 Loss on disposal of fixed assets 116 - Deferred income taxes and tax benefits resulting from the exercise of common stock options 12,456 9,963 Amortization of marketable securities premiums 523 563 Changes in operating assets and liabilities: Membership fees receivable (16,871) (14,446) Prepaid expenses and other current assets (661) (1,103) Deferred incentive compensation (812) (537) Deferred revenues 14,766 14,623 Accounts payable and accrued liabilities (152) 2,181 Accrued incentive compensation 313 512 Other liabilities 1,137 - Net cash flows provided by operating activities 29,026 26,603 Cash flows from investing activities: Purchases of property and equipment (3,964) (1,135) Sales of marketable securities 20,713 6,000 Purchases of marketable securities (22,242) (38,411) Net cash flows used in investing activities (5,493) (33,546) Cash flows from financing activities: Proceeds on issuance of stock from exercise of options 7,343 6,175 Issuance of common stock under employee stock purchase plan 207 240 Purchase of treasury shares (34,671) - Net cash flows (used in) provided by financing activities (27,121) 6,415 Net decrease in cash and cash equivalents (3,588) (528) Cash and cash equivalents, beginning of period 41,389 33,301 Cash and cash equivalents, end of period $37,801 $32,773 Supplemental disclosure of cash flow information: Cash paid during the period for - Income taxes $33 $- The Advisory Board Company Web site: http://www.advisoryboardcompany.com/

Next » | All Messages |  ABCO Message Board Home | Ignore Poster